Z-VRPR-FMK (TFA)

Z-VRPR-FMK (TFA)

• UNSPSC Description: Z-VRPR-FMK (TFA) (VRPR), a tetrapeptide, is a selective and irreversible MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor. Z-VRPR-FMK (TFA) can protect against influenza A virus (IAV) infection[1].
• Target Antigen: Influenza Virus; MALT1
• Type: Peptides
• Related Pathways: Anti-infection;Metabolic Enzyme/Protease;NF-κB
• Applications: COVID-19-anti-virus
• Field of Research: Cancer; Infection
• Assay Protocol: https://www.medchemexpress.com/z-vrpr-fmk-tfa.html
• Purity: 95.92
• Solubility: H2O : 1 mg/mL (ultrasonic;warming)
• Smiles: OC(C(F)(F)F)=O.CC([C@@H](C(N[C@H](C(N1CCC[C@H]1C(NC(C(CF)=O)CCCNC(N)=N)=O)=O)CCCNC(N)=N)=O)NC(OCC2=CC=CC=C2)=O)C
• Molecular Weight: 790.81
• References & Citations: [1]Hatcher JM, et al. Peptide-based covalent inhibitors of MALT1 paracaspase. Bioorg Med Chem Lett. 2019 Jun 1;29(11):1336-1339.
• Shipping Conditions: Blue Ice
• Storage Conditions: -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported